Upstream Bio Reports Widened Q1 Net Loss, Caps COPD Trial Enrollment, Advances Phase 3 Programs

summarizeSummary

Upstream Bio announced Q1 2026 financial results, reporting a widened net loss due to higher R&D, while also updating on its clinical pipeline, including capping enrollment in its Phase 2 COPD trial and advancing two programs to Phase 3.

check_boxKey Events

• Widened Net Loss in Q1 2026

  The company reported a net loss of $40.6 million for the first quarter ended March 31, 2026, compared to a net loss of $27.3 million for the same period in 2025, primarily due to increased R&D expenses.

• Increased R&D Expenses

  Research and development expenses rose to $36.6 million in Q1 2026 from $25.8 million in Q1 2025, driven by clinical and manufacturing costs for verekitug programs.

• Capped Enrollment in Phase 2 COPD Trial

  Upstream Bio will cap further enrollment in its Phase 2 VENTURE trial for COPD, with data now expected in the second half of 2027, indicating a potential re-evaluation or delay for this program.

• Advancing Phase 3 Programs

  The company is rapidly advancing its Phase 3 programs for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with End-of-Phase 2 FDA meetings planned for mid-2026 and Phase 3 initiations expected in Q1 2027.

auto_awesomeAnalysis

Upstream Bio reported a significantly widened net loss for Q1 2026, primarily driven by increased research and development expenses for its verekitug programs. While the company maintains a cash runway through 2027, the decision to cap enrollment and delay data for the Phase 2 COPD trial introduces uncertainty for that program. However, the company is actively progressing its severe asthma and CRSwNP programs towards Phase 3 initiation in Q1 2027, with FDA meetings planned for mid-2026.